The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements.


Journal

Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329

Informations de publication

Date de publication:
11 2019
Historique:
received: 16 04 2019
revised: 18 05 2019
accepted: 20 05 2019
pubmed: 22 5 2019
medline: 15 2 2020
entrez: 22 5 2019
Statut: ppublish

Résumé

NTRK3-rearranged tumors other than infantile fibrosarcomas (IFSs) harboring the canonical ETV6-NTRK3 fusions are uncommon, and include mainly inflammatory myofibroblastic tumors and gastrointestinal stromal tumors. Herein, we describe an additional subset of seven tumors sharing NTRK3 gene rearrangements. The cohort included five females and two males (age range 1-67 years). Tumors were located in extremities, trunk, retroperitoneum, or intra-abdominal. In all tumors, fluorescence in situ hybridization (FISH) revealed rearrangements in NTRK3 accompanied by NTRK3 amplification in two cases. In three cases, RNA sequencing identified a fusion transcript composed of NTRK3 exon 14 fused to ETV6, TFG, and TPM4, respectively, retaining the NTRK3 kinase domain. All tumors were positive for pan-TRK by immunohistochemistry (IHC). Two cases showed low- to intermediate-grade histology composed of monomorphic spindle cells arranged in a patternless architecture, stromal bands, and perivascular rings of hyalinized collagen and coexpression of S100 and CD34. The remaining five cases were high-grade fascicular monomorphic spindle cell sarcomas, morphologically somewhat reminiscent of either malignant peripheral nerve sheath tumors (MPNSTs) or fibrosarcomas (FSs). Two high-grade NTRK3 sarcomas showed aggressive clinical behavior with development of lung metastases. Identification of high-grade NTRK3-rearranged sarcomas is clinically important, since the development of selective NTRK inhibitors has opened new avenues for targeted therapy. Although IHC for pan-TRK can be applied as a screening tool, molecular studies are recommended for a conclusive diagnosis of NTRK-rearranged neoplasms.

Identifiants

pubmed: 31112350
doi: 10.1002/gcc.22767
pmc: PMC6733642
mid: NIHMS1040149
doi:

Substances chimiques

Biomarkers, Tumor 0
Receptor, trkC EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

739-746

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140146
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28097808
Mod Pathol. 2016 Jan;29(1):4-13
pubmed: 26585554
Appl Immunohistochem Mol Morphol. 2008 May;16(3):246-50
pubmed: 18301245
Histopathology. 2016 Jul;69(1):72-83
pubmed: 26647767
Pediatr Dev Pathol. 2018 Jan-Feb;21(1):68-78
pubmed: 28683589
Cancer. 2018 Nov 1;124(21):4241-4247
pubmed: 30204247
Mod Pathol. 2014 Mar;27(3):390-5
pubmed: 24030747
Genes Chromosomes Cancer. 2018 Dec;57(12):611-621
pubmed: 30276917
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Am J Surg Pathol. 2016 Oct;40(10):1407-16
pubmed: 27259011
J Cutan Pathol. 2018 Dec;45(12):933-939
pubmed: 30175468
J Thorac Oncol. 2019 May;14(5):825-834
pubmed: 30550870
J Pathol. 2016 Apr;238(5):700-10
pubmed: 26863915
J Pathol. 2016 Mar;238(4):543-9
pubmed: 26606880
Am J Surg Pathol. 2016 Apr;40(4):479-89
pubmed: 26645727
Nat Genet. 2013 Feb;45(2):180-5
pubmed: 23313952
J Transl Med. 2016 Dec 14;14(1):339
pubmed: 27974047
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
Am J Surg Pathol. 2018 Jun;42(6):791-798
pubmed: 29553955
Am J Surg Pathol. 2019 Apr;43(4):435-445
pubmed: 30585824
Am J Surg Pathol. 2019 Apr;43(4):523-530
pubmed: 30520818
Mod Pathol. 2019 Jul;32(7):1008-1022
pubmed: 30877273
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Histopathology. 2018 Oct;73(4):634-644
pubmed: 29863809

Auteurs

Albert J Suurmeijer (AJ)

Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Brendan C Dickson (BC)

Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.

David Swanson (D)

Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.

Lei Zhang (L)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Yun-Shao Sung (YS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Hsuan-Ying Huang (HY)

Department of Anatomical Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Kaohsiung City, Taiwan.

Christopher D Fletcher (CD)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Cristina R Antonescu (CR)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH